Atley Solutions is a life science technology company providing tools and infrastructure for pharmaceutical companies developing At-211 based radiopharmaceuticals.
Addressing a critical bottleneck in targeted alpha therapy: the reliable and scalable production of At-211 radiopharmaceuticals. Atley commercialises the Atley C100, the world’s first automated system for purification and synthesis of At-211–labelled compounds, complemented by high-quality Bi-209 targets and specialised radiochemistry services. The industrialising and standardising of At-211 manufacturing enables pharmaceutical partners to accelerate clinical development and commercialisation, supporting highly precise cancer irradiation while minimising damage to surrounding healthy tissue.
